The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
The "Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034" report has been added tAndMarkets.com's offering.The report delivers an in-depth understanding of the Cough in ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
Qureight Ltd, the Core Imaging Laboratory developing deep-learning image analytics, and Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies to treat ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Canaccord Genuity has downgraded Pliant (PLRX) to hold following news that the company has paused a clinical trial for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback